SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $111,920,967 | +21.1% | 863,721 | +3.3% | 0.03% | +8.0% |
| Q3 2022 | $92,446,592 | +65.3% | 836,318 | +12.1% | 0.02% | +78.6% |
| Q2 2022 | $55,930,055 | +4.0% | 746,132 | +8.4% | 0.01% | +16.7% |
| Q1 2022 | $53,792,573 | -8.8% | 688,589 | +5.2% | 0.01% | 0.0% |
| Q4 2021 | $58,961,000 | +0.3% | 654,753 | +3.0% | 0.01% | -7.7% |
| Q3 2021 | $58,790,000 | +14.5% | 635,708 | -3.7% | 0.01% | +18.2% |
| Q2 2021 | $51,329,000 | +2.2% | 660,271 | -2.0% | 0.01% | -8.3% |
| Q1 2021 | $50,233,000 | -37.0% | 674,002 | +44.1% | 0.01% | -36.8% |
| Q4 2020 | $79,747,000 | +13.8% | 467,754 | -6.2% | 0.02% | 0.0% |
| Q3 2020 | $70,056,000 | -22.2% | 498,866 | -11.2% | 0.02% | -26.9% |
| Q2 2020 | $90,052,000 | +59.8% | 561,630 | -2.5% | 0.03% | +30.0% |
| Q1 2020 | $56,356,000 | -24.2% | 576,123 | 0.0% | 0.02% | -4.8% |
| Q4 2019 | $74,343,000 | +97.0% | 576,123 | +15.0% | 0.02% | +75.0% |
| Q3 2019 | $37,745,000 | -49.0% | 501,123 | +3.0% | 0.01% | -47.8% |
| Q2 2019 | $73,939,000 | +11.7% | 486,601 | -12.4% | 0.02% | +9.5% |
| Q1 2019 | $66,174,000 | +14.3% | 555,196 | +4.7% | 0.02% | -4.5% |
| Q4 2018 | $57,891,000 | -21.0% | 530,480 | +16.9% | 0.02% | -8.3% |
| Q3 2018 | $73,304,000 | +36.1% | 453,871 | +11.4% | 0.02% | +33.3% |
| Q2 2018 | $53,865,000 | +55.6% | 407,514 | -12.8% | 0.02% | +38.5% |
| Q1 2018 | $34,610,000 | +27.5% | 467,133 | -4.3% | 0.01% | +30.0% |
| Q4 2017 | $27,154,000 | +1.1% | 488,034 | -17.6% | 0.01% | 0.0% |
| Q3 2017 | $26,854,000 | +39.0% | 592,028 | +3.3% | 0.01% | +25.0% |
| Q2 2017 | $19,323,000 | +13.9% | 573,205 | 0.0% | 0.01% | +14.3% |
| Q1 2017 | $16,967,000 | +51.7% | 573,205 | +40.6% | 0.01% | +40.0% |
| Q4 2016 | $11,181,000 | -44.1% | 407,604 | +19.4% | 0.01% | -44.4% |
| Q3 2016 | $20,016,000 | +819.4% | 341,253 | +198.9% | 0.01% | +800.0% |
| Q2 2016 | $2,177,000 | – | 114,178 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |